Inpart Testimonials

  • “Through due diligence, investors and pharma companies take a closer look at their potential partner, the asset, and the deal itself to validate claims and evaluate risks. With many millions of dollars riding on the success of licensing and acquisition activities, a deal gone wrong can mean significant debt and …

  • "Inpart has enabled Lilly to standardize processes, enable more consistent data across the entire External Innovation community and place data more directly into the hands of business development leadership."

  • currently locked
  • currently locked
  • currently locked
  • currently locked
  • currently locked
  • currently locked
  • currently locked
  • currently locked
  • currently locked
  • currently locked
  • currently locked
  • currently locked
  • currently locked